35 Natale JJ et al. Drug-drug interaction
profile of components of fixed combination of
netupitant and palonosetron: Review of clinical
data. J Oncol Pharm Pract 2016;22(3):485–95.
36 Hesketh PJ et al. A review of NEPA, a
novel fixed antiemetic combination with the
potential for enhancing guideline adherence
and improving control of chemotherapy-
induced nausea and vomiting. Biomed Res Int
2015;2015:651879.
37 Akynzeo. Summary of Product
Characteristics. www.medicines.org.uk/emc/
(accessed June 2018).
38 Aapro M et al. A randomized phase III study
evaluating the efficacy and safety of NEPA,
a fixed-dose combination of netupitant and
palonosetron, for prevention of chemotherapy-
induced nausea and vomiting following
moderately emetogenic chemotherapy. Ann
Oncol 2014;25(7):1328–33.
39 Herrstedt J. The latest consensus on
antiemetics. Curr Opin Oncol 2018;30(4):233–9.
40 Navari R. Rolapitant hydrochloride:
prophylactic treatment for chemotherapy-
induced nausea and vomiting. Drugs Today
(Barc) 2016;52(8):431–8.
41 Navari RM et al. Rolapitant for the prevention
of nausea in patients receiving highly or
moderately emetogenic chemotherapy. Cancer
Med 2018;May 23 [Epub ahead of print].
42 US Food and Drug Administration.
Varubi (rolapitant) Injectable Emulsion:
Health Care Provider Letter. www.fda.
gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/
ucm592592.htm (accessed June 2018)
43 Chasen M et al. Rolapitant improves quality
of life of patients receiving highly or moderately
emetogenic chemotherapy. Support Care Cancer
2017;25(1):85–92.
44 Varubi. Summary of Product Characteristics.
http://varubirx.com/ (accessed June 2018).
45 Ito Y et al. Placebo-controlled, double-blinded
Phase III study comparing dexamethasone on
day 1 with dexamethasone on days 1 to 3 with
combined neurokinin-1 receptor antagonist and
palonosetron in high-emetogenic chemotherapy.
J Clin Oncol 2018;36:1000–6.
46 Antonarakis ES et al. Prophylaxis of acute
chemotherapy-induced nausea and vomiting
in children with cancer: what is the evidence?
Pediatr Blood Cancer. 2004;43(6):651–8.
47 Metoclopramide. In: UpToDate, UpToDate,
Waltham, MA, 2017. www.uptodate.com/home/
64 | 2018 | hospitalpharmacyeurope.com
index.html (accessed June 2018).
48 Alizapride. Summary of product
characteristics. www.bcfi.be (accessed June
2018).
4949 Wang SY, Yang ZJ, Zhang L. Olanzapine
for preventing nausea and vomiting induced
by moderately and highly emetogenic
chemotherapy. Asian Pac J Cancer Prev
2014;15(22):9587–92.
50 DeRemer DL et al. Emerging role of
olanzapine for prevention and treatment of
chemotherapy-induced nausea and vomiting.
Pharmacotherapy 2016;36(2):218–29.
51 Yang T et al. Efficacy of olanzapine for the
prophylaxis of chemotherapy-induced nausea
and vomiting: a meta-analysis. Br J Clin
Pharmacol 2017;83(7):1369–79.
52 Navari RM et al. Olanzapine for the
prevention of chemotherapy-induced nausea
and vomiting. N Engl J Med 2016;375:134–42.
53 Bosnjak SM, Dimitrijevic J, Djordjevic F.
Cancer and chemotherapy-induced nausea
and vomiting: a focus on olanzapine. Curr Opin
Support Palliat Care 2016:10(2):180–8.
54 Todaro B. Cannabinoids in the treatment of
chemotherapy-induced nausea and vomiting.
J Natl Compr Cancer Netw 2012;10(4):487–92.
55 Badowski ME. A review of oral cannabinoids
and medical marijuana for the treatment of
chemotherapy-induced nausea and vomiting:
a focus on pharmacokinetic variability and
pharmacodynamics. Cancer Chemother
Pharmacol 2017;80(3):441–9.
56 Haniadka R et al. Zingiber officinale (ginger)
as an anti-emetic in cancer chemotherapy:
a review. J Altern Complement Med
2012;18(5):440–4.
57 Bossi P et al. A randomized, double-
blind, placebo-controlled, multicenter study
of a ginger extract in the management of
chemotherapy-induced nausea and vomiting
(CINV) in patients receiving high-dose cisplatin.
Ann Oncol. 2017;28(10):2547–51.
58 Konmun J et al. A phase II randomized
double-blind placebo-controlled study of
6-gingerol as an anti-emetic in solid tumor
patients receiving moderately to highly
emetogenic chemotherapy. Med Oncol
2017;34(4):69.